Market access strategies for regenerative medicines, and rare and orphan disease treatments are particularly complex. This collection of case studies illustrates some of the challenges and opportunities for manufacturers, including:
- mapping the policy landscape and understand evolving payer requirements for regenerative medicines
- developing value propositions, GVDs, and objections handlers for products indicated for rare diseases
- producing evidence generation plans and prepare HTA submissions using the latest market access technology.